Regis Perichon, Ph.D
About Regis Perichon, Ph.D
Regis Perichon, Ph.D., is the Associate Director of Pharmacodiagnostics, Precision Medicine at Bristol Myers Squibb, with extensive experience in diagnostics and biomarker development.
Title and Current Position
Regis Perichon, Ph.D, currently serves as the Associate Director of Pharmacodiagnostics, Precision Medicine at Bristol Myers Squibb. He operates out of the Summit, New Jersey (Celgene site). In his role, he plays a key role in assessing the mass spectrometry landscape for clinical trial assays (CTA) and companion diagnostics (CDx) activities and goals. He manages the translation of promising biomarkers into clinical trial assays and companion diagnostics in support of Bristol-Myers Squibb's assets in various disease areas.
Professional Experience
Regis Perichon has amassed extensive experience in the biotechnology and pharmaceutical industries. He served as Interim CSO at Sanyal Biotechnology in 2019, Director of Business Development, R&D Services at Juno Metabolomics in 2019, and held multiple roles at Metabolon, Inc., including Director of Product Development - Diagnostics from 2014 to 2019. He has also worked at Ortho Clinical Diagnostics as Manager Proteomics Research from 2007 to 2010, and as Principal Scientist from 2004 to 2007. Additionally, he served as Project Leader at Ciphergen from 2001 to 2004.
Educational Background
Regis Perichon holds a Doctor of Philosophy (Ph.D.) in Biology of Aging from Université Paris Cité. His post-doctoral training includes positions at Johns Hopkins University, Kennedy Krieger Institute, and the National Institutes of Health (NIH). His academic background has provided a solid foundation for his extensive research and development experience in the field of diagnostics and precision medicine.
Scientific Contributions and Innovations
Regis Perichon has significantly contributed to the field of diagnostics. He played a key role in the development and clinical validation of the accuGFR™ test, for estimating glomerular filtration rate (eGFR) independent of traditional markers. He was also instrumental in the successful launch of the Quantose IR™ test for insulin resistance in 2013 and its follow-up product, the Quantose IGT™ test. His efforts in biomarker discovery have led to the filing of five diagnostic biomarker patents covering areas such as kidney function, liver disease, oncology, and infectious diseases.
Strategic and Marketing Roles
In addition to his scientific achievements, Regis Perichon has managed strategic and upstream marketing activities. He has identified unmet diagnostic needs, characterized market size, and developed relationships with top-tier Key Opinion Leaders (KOL) in relevant medical specialties. His work has had a direct impact on product positioning and market understanding, showcasing his ability to bridge scientific innovation with market demands.